Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2022 August Health Innovation Loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma Read more
2022 August Clinical trials Adding elotuzumab to lenalidomide and dexamethasone does not improve PFS in patients with newl... Read more
2022 August Clinical trials LISO-CEL SHOWS SUPERIOR EFFICACY VS. STANDARD OF CARE AS SECOND-LINE TREATMENT FOR PRIMARY REF... Read more
2022 August Clinical trials Adding ibrutinib to bendamustine and rituximab prolongs progression-free survival in older pat... Read more
2022 March Clinical trials ADDING ROMIDEPSIN TO CHOP IN FIRST-LINE TREATMENT OF PERIPHERAL T-CELL LYMPHOMAS DOES NOT IMPR... Read more
2022 March Clinical practice The impact of early venetoclax discontinuation or dose modification on outcomes of patients wi... Read more
Top
